TVRD

+ Watchlist + Portfolio

Tvardi Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.88
52-Week Range: $1.50 – $43.65
Market Cap: $24.41M
P/E (TTM): —
EPS (TTM): -2.87
Dividend Yield: —

Advanced Metrics

Price/Book: 1.18
PEG Ratio: —
Return on Equity: —
Return on Assets: -68.64%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.25
Debt/Equity: 0.01
Total Debt: $174.00K
Free Cash Flow: $-11.57M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-6.98M

TVRD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.47M	$15.87M	$23.65M	$18.01M
Selling, General & Admin	$2.73M	$2.80M	$4.46M	$8.74M
Operating Expenses	$21.19M	$18.66M	$28.11M	$26.75M
Operating Income	-$21.19M	-$18.66M	-$28.11M	-$26.75M
EBITDA	-$20.45M	-$17.25M	-$28.01M	-$26.65M
Pretax Income	-$20.54M	-$17.35M	-$29.40M	-$18.21M
Net Income	-$20.54M	-$17.35M	-$29.40M	-$18.21M
Diluted EPS	-7.98	-6.74	-11.41	-3.26
Diluted Shares	2.58M	2.58M	2.58M	7.78M

TVRD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$21.49M	$22.92M	$31.61M	$20.73M
Current Assets	$44.11M	$26.16M	$31.69M	$31.54M
Total Assets	$45.10M	$27.00M	$35.20M	$32.07M
Current Liabilities	$4.28M	$3.28M	$10.37M	$11.04M
Long-Term Debt	—	—	$30.26M	—
Total Debt	$450.00K	$368.00K	$30.56M	$201.00K
Total Liabilities	$90.15M	$89.06M	$126.33M	$11.13M
Retained Earnings	-$45.49M	-$62.84M	-$92.24M	-$110.45M
Shareholders' Equity	-$45.05M	-$62.06M	-$91.13M	$20.95M
Working Capital	$39.83M	$22.88M	$21.32M	$20.50M

TVRD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.87M	-$21.04M	-$18.30M	-$23.50M
Capital Expenditure	-$50.00K	—	—	—
Free Cash Flow	-$17.92M	-$21.04M	-$18.30M	-$23.50M
Depreciation & Amortisation	$85.00K	$95.00K	$95.00K	$95.00K
Stock-Based Compensation	$246.00K	$314.00K	$319.00K	$1.40M
Investing Cash Flow	-$22.00M	$22.47M	$0.00	-$10.08M
Financing Cash Flow	$4.00K	$2.00K	$27.00M	$22.70M
Net Change in Cash	-$39.86M	$1.43M	$8.70M	-$10.88M

TVRD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	—	—	—	—
Gross Profit	$2.57M	—	—	—	—
Research & Development	$3.11M	$5.81M	$3.60M	$5.49M	$4.91M
Selling, General & Admin	$1.24M	$3.06M	$2.33M	$2.10M	$2.14M
Operating Expenses	$4.35M	$8.87M	$5.94M	$7.59M	$7.05M
Operating Income	-$4.35M	-$8.87M	-$5.94M	-$7.59M	-$7.05M
EBITDA	-$4.33M	-$8.85M	-$5.91M	-$7.56M	-$7.03M
Pretax Income	-$9.58M	$4.17M	-$5.53M	-$7.28M	-$6.80M
Net Income	-$9.58M	$4.17M	-$5.53M	-$7.28M	-$6.80M
Diluted EPS	-3.72	-1.00	-0.59	-0.78	-0.73
Diluted Shares	2.58M	8.46M	9.38M	9.38M	9.38M

TVRD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$34.22M	$1.05M	$21.42M	$20.73M	$19.85M
Receivables	$2.24M	—	—	—	—
Inventory	$900.00K	—	—	—	—
Current Assets	$38.95M	$43.13M	$38.44M	$31.54M	$25.33M
Total Assets	$38.95M	$43.75M	$39.02M	$32.07M	$25.82M
Current Liabilities	$1.20M	$10.68M	$11.04M	$11.04M	$11.26M
Total Debt	—	$254.00K	$228.00K	$201.00K	$174.00K
Total Liabilities	$47.02M	$10.82M	$11.15M	$11.13M	$11.31M
Retained Earnings	-$760.52M	-$97.65M	-$103.17M	-$110.45M	-$117.25M
Shareholders' Equity	-$8.07M	$32.93M	$27.87M	$20.95M	$14.51M
Working Capital	$37.75M	$32.45M	$27.40M	$20.50M	$14.07M

TVRD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.69M	-$5.87M	-$4.26M	-$5.68M	-$5.86M
Free Cash Flow	-$7.69M	-$5.87M	-$4.26M	-$5.68M	-$5.86M
Depreciation & Amortisation	$24.00K	$23.00K	$24.00K	$24.00K	$24.00K
Stock-Based Compensation	$80.00K	$627.00K	$339.00K	$353.00K	$370.00K
Investing Cash Flow	-$10.88M	-$9.55M	$5.35M	$5.00M	$4.98M
Financing Cash Flow	-$1.60M	$24.63M	-$322.00K	$1.00K	$0.00
Net Change in Cash	-$20.18M	$9.21M	$770.00K	-$684.00K	-$883.00K

Market Snapshot

About

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for autoimmune and inflammatory diseases. The company focuses on targeting immune cell trafficking and activation pathways.